Pharma Journalist -

Janssen Research & Development, LLC (Janssen) announced positive results from a randomized, placebo-controlled Phase 2 study investigating the anti-interleukin (IL)-12/23 monoclonal…
Read More...

Stealth BioTherapeutics (Stealth) announced the initiation of MMPOWER-3, a Phase 3 study evaluating the efficacy and safety of daily subcutaneous injections of elamipretide in patients…
Read More...

Boehringer Ingelheim and Dicerna Pharmaceuticals announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the treatment of…
Read More...

The Canadian scientific community gathered in Ottawa this week to engage in a national dialogue on science, technology and innovation policy at the annual Canadian Science Policy…
Read More...

Otsuka Pharmaceutical announced detailed results from the Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). Trial results…
Read More...

SMi's Pre-Filled Syringes Preliminary Attendee List released which will gather an audience of over 100 senior drug delivery and medical device experts. With 280 plus Industry…
Read More...

WuXi Biologics and its partner Pall Corporation established a joint laboratory to develop full continuous processing for the manufacturing of monoclonal antibodies (mAb). The 3-year…
Read More...

AstraZeneca and its global biologics research and development arm, MedImmune, today announced the top-line results of the Phase III STRATOS 2 and TROPOS trials for tralokinumab, an…
Read More...

Visterra announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, VIS410, a novel monoclonal antibody in development…
Read More...

RedHill Biopharma together with IntelGenx announced that they have resubmitted the 505(b)(2) New Drug Application (NDA) for RIZAPORT 10mg to the U.S. Food and Drug Administration (FDA).…
Read More...